Navigation Links
host in Medical Technology

Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis

SOUTH SAN FRANCISCO, Calif., July 8 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced that the Company plans to host a conference call on Thursday, July 9, 2009 at 8:00 am EDT (5:00 am PDT). Members of Rigel's senior management team and the principal investig...

Hooters of Orange Park to Host Charity Car Wash Raising Money for Breast Cancer Research

ATLANTA, May 8 /PRNewswire/ -- On May 9th, the Hooters of Orange Park is hosting a car wash to raise money for breast cancer research. The car wash begins at 10 AM at the Hooters of Orange Park located at 1740 Wells Road. The restaurant can be reached at (904) 215-5858. All donations from t...

PharmAthene to Host a Conference Call and Webcast on Wednesday, April 29th at 4:30 PM to Provide an Update on the SparVax(TM) rPA Anthrax Vaccine Program

ANNAPOLIS, Md., April 28 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP ) a biodefense company developing medical countermeasures against biological and chemical threats, announced today that it will be hosting a conference call for investors on Wednesday, April 29th beginning at ...

Arena Pharmaceuticals to Host Conference Call and Webcast on Monday, March 30, 2009 to Discuss Lorcaserin Pivotal Phase 3 Obesity Trial Results

SAN DIEGO, March 29 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) today announced it will hold a conference call and webcast on Monday, March 30, 2009 at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to discuss top-line results from BLOOM (Behavioral modification and Lo...

Rosetta Genomics Announces Commercial Availability of its First MicroRNA-Based Diagnostic Test; Will Host Teleconference to Discuss Launch of Future Tests

REHOVOT, Israel, JERSEY CITY, New Jersey and PHILADELPHIA, December 11 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (NASDQ: ROSG), a leading developer of microRNA-based molecular diagnostics, announced today the commercial availability of its first diagnostic test, miRview(TM) squamous. Th...

CuraGen to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and CR011-vcMMAE Phase II Trial Results on November 3, 2008

BRANFORD, Conn., Oct. 29 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN ), a clinical-stage biopharmaceutical company focused on oncology, announced today that Company executives will be holding a conference call and webcast at 11:00 a.m. ET on Monday, November 3, 2008 following ...

Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE

BETHESDA, Md., Aug. 18 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, will host a webcast and conference call this morning, Monday, August 18, 200...

Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results

BETHESDA, Md., July 29 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it will host a conference call and audio webcast on Thu...

Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008

SAN DIEGO, July 28 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX ), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it will release its ...

VIRxSYS to Host a Web Conference to Announce Clinical Trial Update

Summary of data from five 2008 conferences GAITHERSBURG, Md., July 21 /PRNewswire/ -- VIRxSYS Corporation, a privately held company developing gene therapies for HIV and genetic diseases, will present an update on the VRX496 Phase I and Phase II clinical trials for the media and...

Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntington's Disease

SAN FRANCISCO, July 3 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN ) today announced that it will hold a teleconference at 5:00 p.m. EDT on Monday, July 7, to discuss top-line results from its randomized, double-blind, placebo-controlled Phase 2 clinical trial of dimebon(TM) in Hu...

TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate

TorreyPines Therapeutics' CEO Neil Kurtz, M.D., to Moderate Discussion Following Presentations by Tony Yaksh, Ph.D.; Jerome Goldstein, M.D.; and Alan J. Tuchman, M.D. LA JOLLA, Calif., June 25 /PRNewswire/ -- A Webinar hosted by TorreyPines Therapeutics, Inc. (Nasdaq:...

Cardica to Host Investor Briefing on 'Revolutionizing Revascularization'

- Event to Be Webcast June 12 at 5:15 p.m. Eastern Time - - PAS-Port(R) System Clinical Data To Be Presented During Late Breaking News Session of International Society for Minimally Invasive Cardiothoracic Surgery Annual Meeting - REDWOOD CITY, Calif., June 9 /P...

Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma

SOUTH SAN FRANCISCO, Calif., June 2 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced that it will host a conference call with simultaneous webcast to discuss the preliminary results of its Phase 2 clinical study of R788, a novel, oral Syk kinase inhibitor,...

Colorado Cancer Research Program Will Host Golf Event to 'Drive' the Message that Clinical Trials Play a Vital Role in the Quest to Find a Cure for Cancer

DENVER, April 28 /PRNewswire-USNewswire/ -- The Colorado Cancer Research Program (CCRP) invites golfers to participate in its second annual "Drive for a Cure" Golf Tournament on May 19 at the Valley Country Club, 14601 Country Club Drive, Aurora. The private club is one of Denver's premier gol...

Deloitte and Nonprofit Roundtable Host Real-World Disaster Exercise as Next Step in Developing Preparedness Plan for Greater Washington Region

Former HHS Secretary Tommy G. Thompson Addresses Executives Before Day-Long Exercise WASHINGTON, Oct. 17 /PRNewswire/ -- Representatives from more than 50 Greater Washington nonprofit organizations meet today with disaster preparedness specialists from Deloitte & T...

Threshold to Host Conference Call to Discuss Results From Clinical Presentations at European Cancer Conference (ECCO)

REDWOOD CITY, Calif., Oct. 3 /PRNewswire-FirstCall/ -- Threshold Pharmaceuticals, Inc. (Nasdaq: THLD ), will host a conference call today at 4:30 p.m. ET to discuss the Phase 2 and Phase 3 presentations that were made at the ECCO proceedings last week. Joining the Company on the conference c...

Acorda Therapeutics to Host Analyst and Investor Reception

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Apr 25, 2007 - Acorda Therapeutics, Inc.(R) (Nasdaq: ACOR) today announced that Dr. Lauren Krupp, Professor of Neurology at Stony Brook University, will present data from Acorda's Phase 3 clinical trial of Fampridine-SR in multiple sclerosis at their analyst and in...

Synta Pharmaceuticals to Host Conference Call Today

LEXINGTON, Mass.--(BUSINESS WIRE)--Jun 5, 2007 - Synta Pharmaceuticals Corp., (NASDAQ: SNTA) a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced it will hold a conference call at 2:30 p.m. (EST)...

Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimer's Disease Study

SAN FRANCISCO, June 05, 2007 /PRNewswire-FirstCall/ -- Medivation, Inc. today announced that it will hold a teleconference at 8:30 a.m. Eastern time on Monday, June 11, to discuss top-line 12-month results from its randomized, double-blind, placebo-controlled Phase 2 clinical trial of Dimebon(TM),...

Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycin's First of Two Phase 3 Pneumonia Trials

CHICAGO, June 29, 2007 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. , today announced that it will host a conference call and live webcast at 10:00 am (EDT) on Monday, July 2, 2007 to discuss data from Trial CL-06, the first of two pivotal Phase 3 clinical trials designed to ass...

Nektar Therapeutics Reports Second Quarter 2009 Financial Results

...acific Time. Details are below: Howard Robin, president and chief executive officer, and John Nicholson, chief financial officer, will host a conference call beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT) on Tuesday, August 4, 2009. To access the confe...

Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C

...component of any future combination treatment regimen for HCV." Conference Call and Webcast Members of Pharmasset's management team will host a conference call today, Friday, July 31, 2009, at 8:00 a.m. ET to discuss the preliminary results of the multiple ascending dose trial with PSI-7851....

R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent

...m the earlier TASKi trials and appear to be manageable. Rigel will host a conference call today at 7PM EDT/ 4PM PDT to discuss these results (see c...atment. Conference Call and Webcast Information Rigel will host a conference call to discuss the R788 TASKi3 Phase 2b clinical trial of R78...

Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results

...he markets open. The announcement will be followed by a live webcast and conference call at 8:00 a.m. Eastern time. Orexigen management will host the call and webcast to discuss the results of these clinical trials and answer questions. The live call may be accessed by phone by calling 1-800-561...

Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial

...in RA in the first half of 2010 with a corporate partner. Rigel will host a conference call today at 8:00am EDT/5:00am PDT to discuss these results (...he disease. Conference Call and Webcast Information Rigel will host a conference call to discuss the R788 TASKi2 Phase 2b clinical trial of R78...

Why Do African-Americans Fare Worse With Cancer? Access and Economics Are Only Part of the Story

...es even when they get identical medical treatment and other confounding socioeconomic factors are controlled for. The finding points to biological or host genetic factors as the potential source of the survival gap. "When you look at the dialogue about the issue of race and cancer survival that's go...

June 2009 Mayo Clinic Women's HealthSource Highlights Summer Skin Problems, Low Vision and Pilates

...OCHESTER, Minn. -- Summer isn't always fun in the sun. Intense sunlight, hot and humid temperatures, poisonous plants and biting insects can cause a host of skin problems. The June issue of Mayo Clinic Women's HealthSource offers ways to prevent and treat common summer skin problems. Heat rash ...

SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

...monitored for infections, and appropriate actions should be taken. The possibility exists for TNF-blocking agents, including SIMPONI, to affect host defenses against infections and malignancies. Treatment with SIMPONI may result in the formation of auto-antibodies and, rarely, in the development o...

Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients

...): Update of an ongoing Phase II study. 14th Congress of the EHA 2009, abstract no. 482 Webcast/Conference Call Micromet will host a webcast/conference call this morning from 9:00 am to 11:00 am U.S. Eastern time to discuss the blinatumomab data presented at the 14th Congress of t...

Micromet Presents Update on Blinatumomab's Response Rate and Duration in a Phase 1 Study in Non-Hodgkin's Lymphoma Patients

...in the Ongoing Phase I Study MT103-104 in Patients with Relapsed NHL. ASH 2008, abstract number 267 Webcast/Conference Call Micromet will host a webcast/conference call this morning from 9:00 am to 11:00 am U.S. Eastern time to discuss the blinatumomab data presented at the 14th Congress of t...

Advanced Life Sciences Announces Outcome of FDA's Anti-Infective Drugs Advisory Committee Review of Restanza(TM) (cethromycin)

... a Prescription Drugs User Fee Act (PDUFA) date of July 31, 2009 for the Restanza NDA. Conference Call Details Advanced Life Sciences will host a conference call and live webcast at 8:30 a.m. Eastern Time on Wednesday, June 3, 2009 to discuss the outcome of the AIDAC Review. The conferenc...

Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction

... Management will host Conference Call at 9:00 AM ET Today CORAL GABLES, Fla., May 29 /PRNe...tail as they are developed." Conference Call The Company will host a conference call today at 9:00 AM ET to discuss the trial results. Partic...

Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer

...rst-Line Treatment of Colorectal Cancer - - Poniard Management Team to host Analyst and Investor Briefing to Discuss Data on Sunday, May 31st - S...ic colorectal cancer." Analyst and Investor Briefing Poniard will host an investor event in Orlando on Sunday, May 31, 2009. Presentations will be...

Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support

...eed to match. CB has many other logistical and clinical advantages, including faster availability, lower incidence and severity of acute graft versus host disease, lower risk of transmitting infections by latent viruses, lack of donor attrition and no risk to the donor. CB is commonly used for pediatric...

FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension

...his year," said Roger Jeffs, Ph.D., United Therapeutics' President and Chief Operating Officer. Conference Call United Therapeutics will host a half-hour teleconference today, May 26, 2009, at 9:00 a.m. Eastern Time. The teleconference is accessible by dialing 877-857-6147, with internation...

Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)

...ct slightly more men than women. There are no medicines approved by the FDA or EMEA for the treatment of IPF. Webcast Details InterMune will host a teleconference and webcast, with accompanying slide presentation, this evening at 9:00 p.m. EDT (6:00 p.m. PDT), in which Dr. Noble will present his...

Juvenile Diabetes Research Foundation to Honor Duane DeSisto of Insulet Corporation and Senator Edward M. Kennedy at 27th Annual Hearts & Heroes Gala

...ation (JDRF), the leader in setting the agenda for diabetes research worldwide and the largest charitable funder and advocate of type 1 research, will host its 27th Annual Hearts & Heroes Gala on Saturday, May 16, 2009 at the Boston Marriott Copley Place. JDRF will pay tribute to Duane DeSisto, Presi...

CMC ICOS Biologics and Implicit Bioscience Ltd Announce IC14 Antibody Manufacturing Agreement and Patent License

...nce Ltd is a public unlisted Australian biopharmaceutical company based in Brisbane (Australia) and Seattle, WA that develops drugs which modulate the host immune response to disease. Its business model is to mitigate both product risk and capital risk, through the in-licensing and development of clinical...

BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results

... expects to provide an update on this study by the end of 2009. Conference Call and Web Cast BioCryst's management team will host a conference call and Web cast on Friday, May 8, 2009, at 8:30 a.m. Eastern Time to discuss the financial results and recent corporate developments. ...
Other Tags
(Date:9/15/2014)... bonds are produced naturally across all kingdoms of life ... a broad range of biological activities. The presence of ... influence on their molecular properties. , One ... to find the late-stage, site-specific incorporation of a halogen ... sp C-H bond (one of the most inert chemical ...
(Date:9/15/2014)... coral reef ecologists fears that reef biodiversity may not ... we once thought. , In an international study published ... Excellence for Coral Reef Studies (Coral CoE) says we ... within reef ecosystems. , In coral reefs, just as ... keep the ecosystem safe and functioning. , Professor ...
(Date:9/15/2014)... assistant professor in the Department of Science and Technology ... Human Sciences at Virginia Tech, has won a 2014 ... study the prospects and problems of creating a global ... Japan,s Fukushima I Nuclear Power Plant in March 2011 ... viewed nuclear emergencies, Schmid said. Three of the plant,s ...
Breaking Biology News(10 mins):Pitt chemical biologist finds new halogenation enzyme 2Specialized species critical for reefs 2'Nuclear disasters don't respect national boundaries' 2
(Date:9/16/2014)... 2014. Kessler Foundation researchers have published a study ... the executive deficits found in individuals with multiple ... for executive deficits in multiple sclerosis? Evidence from ... ahead of print on August 18 by ... Victoria Leavitt, PhD, of the Manhattan Memory Center, ...
(Date:9/16/2014)... prospective study that compared patient-reported outcomes of a ... demonstrates that single fraction radiation therapy (SFRT) is ... (MFRT) when pain, function and quality of life ... the American Society for Radiation Oncology,s (ASTRO,s) 56th ... in patients, pain, function and degree of distress ...
(Date:9/16/2014)... presented at the ESMO 2014 Congress will be published ... to give you a first glimpse of what you ... the leading theme Precision Medicine in Cancer Care. , ... is now possible for an increasing number of cancers. ... a common goal --improved patient outcomes. This is the ...
(Date:9/16/2014)... 2014 The Pain Center of ... Ranking Arizona magazine, has selected Analance ™, ... , With TPC seeing hundreds of thousands of ... that was managed through “home grown” systems trying to ... clinical leadership teams. “Our current tools were not ...
(Date:9/16/2014)... September 16, 2014 Transparency Market Research, ... the global facial care market is expected to report ... report, titled ‘Facial Care Market (By Product Type - ... Cleansing Wipes, Serums and Masks and Others (fade creams, ... Growth, Trends and Forecast 2013 – 2019,’ is now ...
Breaking Medicine News(10 mins):Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 2Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 3Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 4Health News:ESMO 2014 Congress Preview 2Health News:The Pain Center of Arizona (TPC) Implements Analance™ BI for Actionable Intelligence 2Health News:The Pain Center of Arizona (TPC) Implements Analance™ BI for Actionable Intelligence 3Health News:Global Facial Care Market Will Report a CAGR of 6.9% between 2013 and 2019: Transparency Market Research 2Health News:Global Facial Care Market Will Report a CAGR of 6.9% between 2013 and 2019: Transparency Market Research 3
Other Contents